📗 Cite This Artifact
Animal Model Comparison for Neurodegenerative Disease Therapeutics
Overview
Experiment ID: animal-model-comparison-001 Category: Animal Model Comparison Priority: High — Critical evidence gap
Hypothesis
...
Overview
Experiment ID: animal-model-comparison-001 Category: Animal Model Comparison Priority: High — Critical evidence gap
Hypothesis
Different preclinical animal models for [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease) recapitulate different aspects of human pathology, leading to inconsistent translation of therapeutic candidates to clinical success. A systematic head-to-head comparison of multiple models treated with identical therapeutic interventions will identify which models best predict human clinical outcomes.
Background
The translational failure rate in neurodegenerative disease drug development exceeds 95% [1](https://doi.org/10.1126/scitranslmed.aaa7914). A major contributor is the reliance on animal models that incompletely capture human disease pathology. Common models include:
- [APP](/entities/app-protein)/PS1 mice: Amyloid plaques, memory deficits
- 5xFAD mice: Aggressive amyloid pathology, gliosis
- 3xTG mice: Both amyloid and [tau](/proteins/tau) pathology
- A53T α-syn mice: Alpha-synuclein aggregation
- MPTP/6-OHDA models: Dopaminergic neuron loss
- [LRRK2](/entities/lrrk2) transgenic mice: LRRK2 pathology
No systematic comparison exists testing identical therapeutics across multiple models correlated with human tissue data.
Specific Aims
Aim 1: Establish standardized model characterization
Characterize baseline pathology across 6 AD models and 6 PD models using consistent histological, biochemical, and behavioral readouts.
Aim 2: Test reference therapeutics across models
Administer 3 established therapeutic candidates (anti-Aβ antibody, anti-tau ASO, GLP-1 agonist) across all models with identical dosing protocols.
Aim 3: Correlate with human tissue data
Compare animal model responses to human brain bank data from corresponding therapeutic trials.
Experimental Design
Models to Include
Alzheimer's Disease Models:
| Model | Background | Pathology | Source |
|-------|-----------|-----------|--------|
| APP/PS1 | C57BL/6 | Aβ plaques | Jackson Labs |
| 5xFAD | C57BL/6 | Aβ plaques, gliosis | Jackson Labs |
| 3xTG | 129/C57BL/6 | Aβ + tau | Jackson Labs |
| APPNL-G-F | C57BL/6 | Aβ plaques (humanized) | Jackson Labs |
| Tau P301S | C57BL/6 | Tau pathology | Jackson Labs |
| hTau | C57BL/6 | Human tau expression | Jackson Labs |
Parkinson's Disease Models:
| Model | Background | Pathology | Source |
|-------|-----------|-----------|--------|
| A53T α-syn | C57BL/6 | α-syn aggregation | Jackson Labs |
| MPTP-treated | C57BL/6 | DA neuron loss | Induced |
| 6-OHDA-treated | SD rats | DA neuron loss | Induced |
| LRRK2 G2019S tg | C57BL/6 | LRRK2 pathology | Jackson Labs |
| Pink1 knockout | C57BL/6 | Mitophagy deficits | Jackson Labs |
| α-syn preformed fibrils | C57BL/6 | Propagation model | Induced |
Treatment Groups (per model)
- Control: Vehicle treatment
- Reference therapeutic 1: Anti-Aβ antibody (or isotype control)
- Reference therapeutic 2: Anti-tau ASO (or scramble)
- Reference therapeutic 3: GLP-1 agonist (or vehicle)
Readouts
Histopathology:
- Amyloid plaques (Thioflavin S, 6E10)
- Tau pathology (AT8, PHF-1)
- α-syn pathology (pSer129)
- Neuronal counts (NeuN)
- Gliosis (Iba1, GFAP)
- Aβ ELISA ([Aβ40](/proteins/amyloid-beta), Aβ42)
- Tau/phospho-tau Western blot
- α-syn/pSer129 Western blot
- Cytokine array
- Morris water maze (AD models)
- Rotarod (motor function)
- Cylinder test (PD models)
- Open field
-[NfL](/biomarkers/neurofilament-light-chain-nfl), tau, Aβ42/40 ratio
Detailed Protocol
Phase 1: Model Characterization (Months 1-3)
Phase 2: Therapeutic Testing (Months 4-18)
- Start at 6 months of age
- Weekly ip injections (antibody/agonist) or intracerebroventricular infusion (ASO)
- Terminal endpoint at 9 months
- Start at 6 months of age
- Same treatment paradigm
- Terminal endpoint at 12 months
Phase 3: Human Correlation (Months 15-24)
Reagents and Costs
Animal Costs
| Item | Cost |
|------|------|
| APP/PS1 mice (100) | $12,000 |
| 5xFAD mice (100) | $12,000 |
| 3xTG mice (100) | $15,000 |
| A53T α-syn mice (100) | $18,000 |
| MPTP model (50) | $8,000 |
| Other models (200) | $30,000 |
| Subtotal | $95,000 |
Therapeutic Reagents
| Item | Cost |
|------|------|
| Anti-Aβ antibody (10mg) | $25,000 |
| Anti-tau ASO (5mg) | $30,000 |
| GLP-1 agonist (liraglutide) | $8,000 |
| Vehicle/isotype controls | $5,000 |
| Subtotal | $68,000 |
Personnel
| Role | Months | Cost |
|------|--------|------|
| PI (25% effort) | 24 | $60,000 |
| Postdoc | 24 | $120,000 |
| Research associate | 24 | $96,000 |
| Veterinary staff | 12 | $36,000 |
| Subtotal | | $312,000 |
Equipment & Supplies
| Item | Cost |
|------|------|
| Behavioral equipment | $40,000 |
| Histology supplies | $25,000 |
| ELISA/Western blot kits | $20,000 |
| Consumables | $30,000 |
| Subtotal | $115,000 |
Other Costs
| Item | Cost |
|------|------|
| Animal housing (24 months) | $72,000 |
| Human tissue acquisition | $40,000 |
| Data analysis software | $8,000 |
| Publication costs | $5,000 |
| Subtotal | $125,000 |
Total Cost: $715,000
Timeline
| Phase | Duration | Milestone |
|-------|----------|-----------|
| Phase 1 | Months 1-3 | Models characterized |
| Phase 2a | Months 4-9 | Cohort 1 complete |
| Phase 2b | Months 10-18 | Cohort 2 complete |
| Phase 3 | Months 15-24 | Human correlation complete |
| Analysis | Months 22-26 | Final analysis and publication |
Total: 26 months
Suggested Investigators
Alzheimer's Disease
Parkinson's Disease
Biostatistics
Geographic Diversity
- USA: 4 investigators
- Europe: 2 investigators (UK, Netherlands)
- Australia: 1 investigator
Scoring (10 Dimensions)
| Dimension | Score (1-10) | Rationale |
|-----------|--------------|-----------|
| Scientific Value | 10 | Addresses fundamental translation gap |
| Feasibility | 8 | Well-established models, proven therapeutics |
| Novelty | 9 | First systematic cross-model comparison |
| Cost Efficiency | 8 | High impact per dollar — reduces future failures |
| Translation Potential | 10 | Direct impact on clinical trial design |
| Resource Requirements | 7 | Requires multiple model colonies |
| Risk Level | 6 | Some models may not respond to treatments |
| Generalizability | 9 | Findings applicable to all neurodegenerative diseases |
| Biomarker Potential | 8 | Identifies predictive biomarkers |
| Patient Relevance | 10 | Improves probability of clinical success |
Total Score: 85/100
Cross-Links to Related Wiki Pages
- [Animal Models Overview](/animal-models/)
- [APP/PS1 Transgenic Mouse](/animal-models/app-ps1-transgenic-mouse)
- [Alpha-Synuclein Models](/proteins/alpha-synuclein)
- [TREM2 Pathway](/proteins/trem2-protein)
- [GLP-1 Receptor Agonists](/therapeutics/glp1-receptor-agonists)
- [Alzheimer's Disease Clinical Trials](/clinical-trials/)
- [Parkinson's Disease Therapeutic Targets](/therapeutics/)
See Also
- [Mechanisms](/mechanisms)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [ClinicalTrials.gov](https://clinicaltrials.gov/)
Follow-up Research
This experiment should be followed by validation in non-human primates to confirm findings before clinical trial design. Created: 2026-03-21 | Slot 1
References
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | experiments-animal-model-comparison-neurodegeneration |
| kg_node_id | None |
| entity_type | experiment |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-4989505c8e25 |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'experiments-animal-model-comparison-neurodegeneration'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-experiments-animal-model-comparison-neurodegeneration?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[Animal Model Comparison for Neurodegenerative Disease Therapeutics](http://scidex.ai/artifact/wiki-experiments-animal-model-comparison-neurodegeneration)
http://scidex.ai/artifact/wiki-experiments-animal-model-comparison-neurodegeneration